KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Assets (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Non-Current Assets data on record, last reported at $14.3 billion in Q3 2025.

  • For Q3 2025, Non-Current Assets changed N/A year-over-year to $14.3 billion; the TTM value through Sep 2025 reached $42.8 billion, changed N/A, while the annual FY2024 figure was $12.9 billion, 50.67% up from the prior year.
  • Non-Current Assets reached $14.3 billion in Q3 2025 per VRTX's latest filing, up from $12.9 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $14.3 billion in Q3 2025 and bottomed at $3.6 billion in Q1 2021.
  • Average Non-Current Assets over 5 years is $8.6 billion, with a median of $7.8 billion recorded in 2023.
  • Peak YoY movement for Non-Current Assets: skyrocketed 74.65% in 2023, then surged 50.67% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $3.6 billion in 2021, then skyrocketed by 37.48% to $4.9 billion in 2022, then skyrocketed by 74.65% to $8.6 billion in 2023, then soared by 50.67% to $12.9 billion in 2024, then rose by 10.48% to $14.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $14.3 billion in Q3 2025, $12.9 billion in Q4 2024, and $8.6 billion in Q4 2023.